血小板单采与补液治疗神经外科ICU继发性血小板增多症疗效比较
本研究回顾性纳入2020年4月至2024年7月皖南医学院第一附属医院神经外科ICU的68例继发性血小板增多症患者,比较血小板单采(n=31)与补液(n=37)的疗效。血小板单采在降低血小板计数(64% vs. 55%,P<0.001)和血小板压积(65% vs. 55%,P<0.001)方面优于补液,且治疗周期更少、NSICU及总住院时间更短、住院费用更低;3个月功能结局两组相当。
要点
- 血小板单采降低血小板计数和血小板压积的幅度显著优于补液。
- 血小板单采组治疗周期更少、NSICU及总住院时间更短、住院费用更低。
- 两组3个月改良Rankin量表评分相当,功能结局无显著差异。
核心结论
- 对于神经重症继发性血小板增多症患者,血小板单采可能是快速降低血小板的优选治疗方式,具有靶向细胞减灭、安全性良好和资源效率更优的特点。
研究设计与样本
- 回顾性队列研究,纳入2020年4月至2024年7月皖南医学院第一附属医院神经外科ICU的68例继发性血小板增多症患者,分为血小板单采组(n=31)和补液组(n=37)。
主要发现
- 血小板单采组血小板计数降幅为64%,补液组为55%(P<0.001)。
- 血小板单采组血小板压积降幅为65%,补液组为55%(P<0.001)。
- 补液组中性粒细胞降幅为55%、单核细胞降幅为50%,血小板单采组分别为25%和17%(P<0.001)。
- 血小板单采组治疗周期更少、NSICU及总住院时间更短、住院费用更低。
- 两组3个月改良Rankin量表评分相当。
临床怎么用
- 神经重症继发性血小板增多症需快速降低血小板时,可优先考虑血小板单采。
局限性
- 本文为单中心回顾性队列研究,样本量68例,结论需多中心随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary thrombocytosis (ST) is associated with increased thromboembolic risk in neurocritical care settings; however, its optimal management remains a subject of debate. We aimed to compare the therapeutic efficacy and clinical outcomes of plateletpheresis versus rehydration therapy in patients with ST. METHODS: A retrospective cohort study was conducted in the neurosurgical intensive care unit (NSICU) of the First Affiliated Hospital of Wannan Medical College from April 2020 to July 2024. A total of 68 patients with ST were enrolled and allocated to the plateletpheresis group (n = 31) or the rehydration group (n = 37). The primary endpoints were changes in complete blood count parameters. Secondary outcomes included NSICU and total hospital length of stay, hospitalization costs, and 3-month modified Rankin Scale scores. RESULTS: Both interventions demonstrated significant efficacy in managing ST. Plateletpheresis yielded superior cytoreductive effects, with greater reductions in platelet count (64% vs. 55%; P < 0.001) and plateletcrit (65% vs. 55%; P < 0.001) compared to rehydration. In contrast, rehydration produced nonspecific hematological effects, notably a significant decrease in leukocyte subpopulations-neutrophils (55% vs. 25%) and monocytes (50% vs. 17%) (P < 0.001). Clinically, plateletpheresis was associated with lower treatment cycles, shorter NSICU and hospital stays, as well as reduced hospitalization costs. Functional outcomes at 3 months were comparable between the groups. CONCLUSIONS: Plateletpheresis appears to be the preferred therapeutic approach for rapid platelet reduction in neurocritical patients with ST, offering targeted cytoreduction, a favorable safety profile, and improved resource efficiency. Further validation through multicenter randomized controlled trials is warranted.
引用
- Yu Z, Tao Y, Zhu M, et al. Comparative Efficacy of Plateletpheresis and Rehydration for Managing Secondary Thrombocytosis in the Neurosurgical Intensive Care Unit. World Neurosurg. 2025. PMID: 40845945. doi:10.1016/j.wneu.2025.124380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。